Clinical Trial Update: Estrogen and Graft Atherosclerosis Research Trial (EAGER) [Phase 3]

View source ↗

Summary

Phase 3 trial EAGER evaluating estrogen for graft atherosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Coronary Arteriosclerosis
• Coronary Artery Disease
• Heart Disease
• Myocardial Ischemia

Drugs mentioned

• Estrogen (Estrogen)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Coronary Arteriosclerosis | Phase 3 | Status: COMPLETED